Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
April 28, 2020
No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion